SCHEDULE: Barclays PLC Discloses Cartesian Therapeutics Stake

Barclays PLC has filed a Schedule 13G, reporting beneficial ownership of 5.99% of Cartesian Therapeutics Inc. common stock as of June 30, 2026.

Summary

• Barclays PLC has filed a Schedule 13G, indicating a change in its beneficial ownership of Cartesian Therapeutics Inc. common stock.
• As of June 30, 2026, Barclays PLC beneficially owns 1,760,326 shares, representing 5.99% of the class of securities.
• This ownership includes sole voting and dispositive power over 1,739,724 shares and shared power over 20,602 shares.
• The filing is made under Rule 13d-1(b), classifying Barclays PLC as a 'HC' (likely referring to a holding company or financial institution) and a non-U.S. institution.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a change in beneficial ownership without providing operational or financial updates.

Positives

• Barclays PLC's filing provides transparency regarding its significant stake in Cartesian Therapeutics Inc.
• The reported ownership of 5.99% suggests a notable investment position.

Negatives

• The filing does not provide any operational or financial performance data for Cartesian Therapeutics Inc.
• The nature of Barclays PLC's investment (e.g., for trading, long-term investment, or advisory) is not detailed.

Risks

• Potential for increased market activity or price volatility in Cartesian Therapeutics Inc. stock due to the disclosure of a significant institutional holder.
• The filing does not offer insights into the strategic intentions of Barclays PLC concerning its stake, which could pose uncertainty for other investors.

Future Outlook

No forward-looking statements or guidance are provided in this Schedule 13G filing.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and indicate passive ownership stakes. The disclosure by Barclays PLC, a major global financial institution, suggests a significant interest in Cartesian Therapeutics Inc.'s common stock, though the specific investment strategy remains undisclosed.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional holder may influence investor sentiment and trading activity.
• Management of Cartesian Therapeutics Inc.: Awareness of Barclays PLC's substantial stake could impact strategic discussions and corporate governance considerations.

Next Steps

• Barclays PLC will continue to hold its beneficial ownership of Cartesian Therapeutics Inc. common stock.
• Further filings may be required if Barclays PLC's beneficial ownership changes significantly.

Key Dates

Keywords

Barclays PLC, Cartesian Therapeutics Inc, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Securities Exchange Act